>PH327906.1 JP 2023535163-A/63: SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS
TACAATCCCTC

>PH327857.1 JP 2023535163-A/14: SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS
ATGTCAAGCTCTTCCTGGCTCCTTCTCAGCCTTGTTGCTGTAACTGCTGCTCAGTCCACCATTGAGGAAC
AGGCCAAGACATTTTTGGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTC
TTGGAATTATAACACCAATATTACTGAAGAGAATGTCCAAAACATGAATAATGCTGGGGACAAATGGTCT
GCCTTTTTAAAGGAACAGTCCACACTTGCCCAAATGTATCCACTACAAGAAATTCAGAATCTCACAGTCA
AGCTTCAGCTGCAGGCTCTTCAGCAAAATGGGTCTTCAGTGCTCTCAGAAGACAAGAGCAAACGGTTGAA
CACAATTCTAAATACAATGAGCACCATCTACAGTACTGGAAAAGTTTGTAACCCAGATAATCCACAAGAA
TGCTTATTACTTGAACCAGGTTTGAATGAAATAATGGCAAACAGTTTAGACTACAATGAGAGGCTCTGGG
CTTGGGAAAGCTGGAGATCTGAGGTCGGCAAGCAGCTGAGGCCATTATATGAAGAGTATGTGGTCTTGAA
AAATGAGATGGCAAGAGCAAATCATTATGAGGACTATGGGGATTATTGGAGAGGAGACTATGAAGTAAAT
GGGGTAGATGGCTATGACTACAGCCGCGGCCAGTTGATTGAAGATGTGGAACATACCTTTGAAGAGATTA
AACCATTATATGAACATCTTCATGCCTATGTGAGGGCAAAGTTGATGAATGCCTATCCTTCCTATATCAG
TCCAATTGGATGCCTCCCTGCTCATTTGCTTGGTGATATGTGGGGTAGATTTTGGACAAATCTGTACTCT
TTGACAGTTCCCTTTGGACAGAAACCAAACATAGATGTTACTGATGCAATGGTGGACCAGGCCTGGGATG
CACAGAGAATATTCAAGGAGGCCGAGAAGTTCTTTGTATCTGTTGGTCTTCCTAATATGACTCAAGGATT
CTGGGAAAATTCCATGCTAACGGACCCAGGAAATGTTCAGAAAGCAGTCTGCCATCCCACAGCTTGGGAC
CTGGGGAAGGGCGACTTCAGGATCCTTATGTGCACAAAGGTGACAATGGACGACTTCCTGACAGCTCATC
ATGAGATGGGGCATATCCAGTATGATATGGCATATGCTGCACAACCTTTTCTGCTAAGAAATGGAGCTAA
TGAAGGATTCCATGAAGCTGTTGGGGAAATCATGTCACTTTCTGCAGCCACACCTAAGCATTTAAAATCC
ATTGGTCTTCTGTCACCCGATTTTCAAGAAGACAATGAAACAGAAATAAACTTCCTGCTCAAACAAGCAC
TCACGATTGTTGGGACTCTGCCATTTACTTACATGTTAGAGAAGTGGAGGTGGATGGTCTTTAAAGGGGA
AATTCCCAAAGACCAGTGGATGAAAAAGTGGTGGGAGATGAAGCGAGAGATAGTTGGGGTGGTGGAACCT
GTGCCCCATGATGAAACATACTGTGACCCCGCATCTCTGTTCCATGTTTCTAATGATTACTCATTCATTC
GATATTACACAAGGACCCTTTACCAATTCCAGTTTCAAGAAGCACTTTGTCAAGCAGCTAAACATGAAGG
CCCTCTGCACAAATGTGACATCTCAAACTCTACAGAAGCTGGACAGAAACTGTTCAATATGCTGAGGCTT
GGAAAATCAGAACCCTGGACCCTAGCATTGGAAAATGTTGTAGGAGCAAAGAACATGAATGTAAGGCCAC
TGCTCAACTACTTTGAGCCCTTATTTACCTGGCTGAAAGACCAGAACAAGAATTCTTTTGTGGGATGGAG
TACCGACTGGAGTCCATATGCAGACCAAAGCATCAAAGTGAGGATAAGCCTAAAATCAGCTCTTGGAGAT
AAAGCATATGAATGGAACGACAATGAAATGTACCTGTTCCGATCATCTGTTGCATATGCTATGAGGCAGT
ACTTTTTAAAAGTAAAAAATCAGATGATTCTTTTTGGGGAGGAGGATGTGCGAGTGGCTAATTTGAAACC
AAGAATCTCCTTTAATTTCTTTGTCACTGCACCTAAAAATGTGTCTGATATCATTCCTAGAACTGAAGTT
GAAAAGGCCATCAGGATGTCCCGGAGCCGTATCAATGATGCTTTCCGTCTGAATGACAACAGCCTAGAGT
TTCTGGGGATACAGCCAACACTTGGACCTCCTAACCAGCCCCCTGTTTCCATATGGCTGATTGTTTTTGG
AGTTGTGATGGGAGTGATAGTGGTTGGCATTGTCATCCTGATCTTCACTGGGATCAGAGATCGGAAGAAG
AAAAATAAAGCAAGAAGTGGAGAAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAAAATAATCCAG
GATTCCAAAACACTGATGATGTTCAGACCTCCTTTTAA

>PI050044.1 JP 2023551821-A/2: METHODS AND COMPOSITIONS FOR TREATING SARS-CoV-2 INFECTION
ATGAAACTTGTCTTCCTCGTCCTGCTGTTCCTCGGGGCCCTCGGACTGTGTCTGGCTGGCCGTAGGAGAA
GGAGTGTTCAGTGGTGCGCCGTATCCCAACCCGAGGCCACAAAATGCTTCCAATGGCAAAGGAATATGAG
AAAAGTGCGTGGCCCTCCTGTCAGCTGCATAAAGAGAGACTCCCCCATCCAGTGTATCCAGGCCATTGCG
GAAAACAGGGCCGATGCTGTGACCCTTGATGGTGGTTTCATATACGAGGCAGGCCTGGCCCCCTACAAAC
TGCGACCTGTAGCGGCGGAAGTCTACGGGACCGAAAGACAGCCACGAACTCACTATTATGCCGTGGCTGT
GGTGAAGAAGGGCGGCAGCTTTCAGCTGAACGAACTGCAAGGTCTGAAGTCCTGCCACACAGGCCTTCGC
AGGACCGCTGGATGGAATGTCCCTATAGGGACACTTCGTCCATTCTTGAATTGGACGGGTCCACCTGAGC
CCATTGAGGCAGCTGTGGCCAGGTTCTTCTCAGCCAGCTGTGTTCCCGGTGCAGATAAAGGACAGTTCCC
CAACCTGTGTCGCCTGTGTGCGGGGACAGGGGAAAACAAATGTGCCTTCTCCTCCCAGGAACCGTACTTC
AGCTACTCTGGTGCCTTCAAGTGTCTGAGAGACGGGGCTGGAGACGTGGCTTTTATCAGAGAGAGCACAG
TGTTTGAGGACCTGTCAGACGAGGCTGAAAGGGACGAGTATGAGTTACTCTGCCCAGACAACACTCGGAA
GCCAGTGGACAAGTTCAAAGACTGCCATCTGGCCCGGGTCCCTTCTCATGCCGTTGTGGCACGAAGTGTG
AATGGCAAGGAGGATGCCATCTGGAATCTTCTCCGCCAGGCACAGGAAAAGTTTGGAAAGGACAAGTCAC
CGAAATTCCAGCTCTTTGGCTCCCCTAGTGGGCAGAAAGATCTGCTGTTCAAGGACTCTGCCATTGGGTT
TTCGAGGGTGCCCCCGAGGATAGATTCTGGGCTGTACCTTGGCTCCGGCTACTTCACTGCCATCCAGAAC
TTGAGGAAAAGTGAGGAGGAAGTGGCTGCCCGGCGTGCGCGGGTCGTGTGGTGTGCGGTGGGCGAGCAGG
AGCTGCGCAAGTGTAACCAGTGGAGTGGCTTGAGCGAAGGCAGCGTGACCTGCTCCTCGGCCTCCACCAC
AGAGGACTGCATCGCCCTGGTGCTGAAAGGAGAAGCTGATGCCATGAGTTTGGATGAAGGATATGTGTAC
ACTGCAGGCAAATGTGGTTTGGTGCCTGTCCTGGCAGAGAACTACAAATCCCAACAAAGCAGTGACCCTG
ATCCTAACTGTGTGGATAGACCTGTGGAAGGATATCTTGCTGTGGCGGTGGTTAGGAGATCAGACACTAG
CCTTACCTGGAACTCTGTGAAAGGCAAGAAGTCCTGCCACACCGCCGTGGACAGGACTGCAGGCTGGAAT
ATCCCCATGGGCCTGCTCTTCAACCAGACGGGCTCCTGCAAATTTGATGAATATTTCAGTCAAAGCTGTG
CCCCTGGGTCTGACCCGAGATCTAATCTCTGTGCTCTGTGTATTGGCGACGAGCAGGGTGAGAATAAGTG
CGTGCCCAACAGCAACGAGAGATACTACGGCTACACTGGGGCTTTCCGGTGCCTGGCTGAGAATGCTGGA
GACGTTGCATTTGTGAAAGATGTCACTGTCTTGCAGAACACTGATGGAAATAACAATGAGGCATGGGCTA
AGGATTTGAAGCTGGCAGACTTTGCGCTGCTGTGCCTCGATGGCAAACGGAAGCCTGTGACTGAGGCTAG
AAGCTGCCATCTTGCCATGGCCCCGAATCATGCCGTGGTGTCTCGGATGGATAAGGTGGAACGCCTGAAA
CAGGTGTTGCTCCACCAACAGGCTAAATTTGGGAGAAATGGATCTGACTGCCCGGACAAGTTTTGCTTAT
TCCAGTCTGAAACCAAAAACCTTCTGTTCAATGACAACACTGAGTGTCTGGCCAGACTCCATGGCAAAAC
AACATATGAAAAATATTTGGGACCACAGTATGTCGCAGGCATTACTAATCTGAAAAAGTGCTCAACCTCC
CCCCTCCTGGAAGCCTGTGAATTCCTCAGGAAGTAA

>PH403602.1 JP 2023528561-A/14: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
AGGGGCCATCCACAGTCTTC

>PH403601.1 JP 2023528561-A/13: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
AGAAGGCTGGGGCTCATTTG

>PH403600.1 JP 2023528561-A/12: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
CCAGGTCACCAGACTCCTCA

>PH403599.1 JP 2023528561-A/11: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
GGAATACACAACCTACTAGCC

>PH403598.1 JP 2023528561-A/10: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
AGGCCTCAGCCTCTTGTG

>PH403597.1 JP 2023528561-A/9: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
GAAGGCAGCTCACGAAACC

>PH403596.1 JP 2023528561-A/8: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
CACAAAGCCTGGCAGCTCTCTA

>PH403595.1 JP 2023528561-A/7: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
GGCTGTTTACCAGACTCCGACA

>PH403594.1 JP 2023528561-A/6: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
AGAAGCGACTCTTCTAAGGCATCTT

>PH403593.1 JP 2023528561-A/5: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
CTGCCACATAGCCCAGTTCA

>PH403592.1 JP 2023528561-A/4: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
AGGTTCCCATCGGCCACATA

>PH403591.1 JP 2023528561-A/3: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
GAGGCCCCCAAAAAGGAGTC

>PH403590.1 JP 2023528561-A/2: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
CCGCTACATCTGAATGACCTG

>PH403589.1 JP 2023528561-A/1: INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS Of HOST CELLS AND FORMULATIONS TO TREAT COVID-19
TGGCTTTTCAGCTCTGCATC

>PH256943.1 JP 2023528072-A/4: Therapeutic antibodies with neutralizing activity against SARS-CoV-2 Glycoprotein S
ATGTCAAGCTCTTCCTGGCTCCTTCTCAGCCTTGTTGCTGTAACTGCTGCTCAGTCCACCATTGAGGAAC
AGGCCAAGACATTTTTGGACAAGTTTAACCACGAAGCCGAAGACCTGTTCTATCAAAGTTCACTTGCTTC
TTGGAATTATAACACCAATATTACTGAAGAGAATGTCCAAAACATGAATAATGCTGGGGACAAATGGTCT
GCCTTTTTAAAGGAACAGTCCACACTTGCCCAAATGTATCCACTACAAGAAATTCAGAATCTCACAGTCA
AGCTTCAGCTGCAGGCTCTTCAGCAAAATGGGTCTTCAGTGCTCTCAGAAGACAAGAGCAAACGGTTGAA
CACAATTCTAAATACAATGAGCACCATCTACAGTACTGGAAAAGTTTGTAACCCAGATAATCCACAAGAA
TGCTTATTACTTGAACCAGGTTTGAATGAAATAATGGCAAACAGTTTAGACTACAATGAGAGGCTCTGGG
CTTGGGAAAGCTGGAGATCTGAGGTCGGCAAGCAGCTGAGGCCATTATATGAAGAGTATGTGGTCTTGAA
AAATGAGATGGCAAGAGCAAATCATTATGAGGACTATGGGGATTATTGGAGAGGAGACTATGAAGTAAAT
GGGGTAGATGGCTATGACTACAGCCGCGGCCAGTTGATTGAAGATGTGGAACATACCTTTGAAGAGATTA
AACCATTATATGAACATCTTCATGCCTATGTGAGGGCAAAGTTGATGAATGCCTATCCTTCCTATATCAG
TCCAATTGGATGCCTCCCTGCTCATTTGCTTGGTGATATGTGGGGTAGATTTTGGACAAATCTGTACTCT
TTGACAGTTCCCTTTGGACAGAAACCAAACATAGATGTTACTGATGCAATGGTGGACCAGGCCTGGGATG
CACAGAGAATATTCAAGGAGGCCGAGAAGTTCTTTGTATCTGTTGGTCTTCCTAATATGACTCAAGGATT
CTGGGAAAATTCCATGCTAACGGACCCAGGAAATGTTCAGAAAGCAGTCTGCCATCCCACAGCTTGGGAC
CTGGGGAAGGGCGACTTCAGGATCCTTATGTGCACAAAGGTGACAATGGACGACTTCCTGACAGCTCATC
ATGAGATGGGGCATATCCAGTATGATATGGCATATGCTGCACAACCTTTTCTGCTAAGAAATGGAGCTAA
TGAAGGATTCCATGAAGCTGTTGGGGAAATCATGTCACTTTCTGCAGCCACACCTAAGCATTTAAAATCC
ATTGGTCTTCTGTCACCCGATTTTCAAGAAGACAATGAAACAGAAATAAACTTCCTGCTCAAACAAGCAC
TCACGATTGTTGGGACTCTGCCATTTACTTACATGTTAGAGAAGTGGAGGTGGATGGTCTTTAAAGGGGA
AATTCCCAAAGACCAGTGGATGAAAAAGTGGTGGGAGATGAAGCGAGAGATAGTTGGGGTGGTGGAACCT
GTGCCCCATGATGAAACATACTGTGACCCCGCATCTCTGTTCCATGTTTCTAATGATTACTCATTCATTC
GATATTACACAAGGACCCTTTACCAATTCCAGTTTCAAGAAGCACTTTGTCAAGCAGCTAAACATGAAGG
CCCTCTGCACAAATGTGACATCTCAAACTCTACAGAAGCTGGACAGAAACTGTTCAATATGCTGAGGCTT
GGAAAATCAGAACCCTGGACCCTAGCATTGGAAAATGTTGTAGGAGCAAAGAACATGAATGTAAGGCCAC
TGCTCAACTACTTTGAGCCCTTATTTACCTGGCTGAAAGACCAGAACAAGAATTCTTTTGTGGGATGGAG
TACCGACTGGAGTCCATATGCAGACCAAAGCATCAAAGTGAGGATAAGCCTAAAATCAGCTCTTGGAGAT
AAAGCATATGAATGGAACGACAATGAAATGTACCTGTTCCGATCATCTGTTGCATATGCTATGAGGCAGT
ACTTTTTAAAAGTAAAAAATCAGATGATTCTTTTTGGGGAGGAGGATGTGCGAGTGGCTAATTTGAAACC
AAGAATCTCCTTTAATTTCTTTGTCACTGCACCTAAAAATGTGTCTGATATCATTCCTAGAACTGAAGTT
GAAAAGGCCATCAGGATGTCCCGGAGCCGTATCAATGATGCTTTCCGTCTGAATGACAACAGCCTAGAGT
TTCTGGGGATACAGCCAACACTTGGACCTCCTAACCAGCCCCCTGTTTCCATATGGCTGATTGTTTTTGG
AGTTGTGATGGGAGTGATAGTGGTTGGCATTGTCATCCTGATCTTCACTGGGATCAGAGATCGGAAGAAG
AAAAATAAAGCAAGAAGTGGAGAAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAAAATAATCCAG
GATTCCAAAACACTGATGATGTTCAGACCTCCTTTTAG

>PG355235.1 JP 2023526495-A/26: SARS-COV-2 VACCINES
GGCCCAACCGCCGCCCGCGCCCCCGCTCTCCGCACCGTACCCGGCCGCCTCGCGCCATGGCGGCCCCCGG
CAGCGCCCGGCGACCCCTGCTGCTGCTACTGCTGTTGCTGCTGCTCGGCCTCATGCATTGTGCGTCAGCA
GCAATGTTTATGGTGAAAAATGGCAACGGGACCGCGTGCATAATGGCCAACTTCTCTGCTGCCTTCTCAG
TGAACTACGACACCAAGAGTGGCCCTAAGAACATGACCTTTGACCTGCCATCAGATGCCACAGTGGTGCT
CAACCGCAGCTCCTGTGGAAAAGAGAACACTTCTGACCCCAGTCTCGTGATTGCTTTTGGAAGAGGACAT
ACACTCACTCTCAATTTCACGAGAAATGCAACACGTTACAGCGTCCAGCTCATGAGTTTTGTTTATAACT
TGTCAGACACACACCTTTTCCCCAATGCGAGCTCCAAAGAAATCAAGACTGTGGAATCTATAACTGACAT
CAGGGCAGATATAGATAAAAAATACAGATGTGTTAGTGGCACCCAGGTCCACATGAACAACGTGACCGTA
ACGCTCCATGATGCCACCATCCAGGCGTACCTTTCCAACAGCAGCTTCAGCAGGGGAGAGACACGCTGTG
AACAAGACAGGCCTTCCCCAACCACAGCGCCCCCTGCGCCACCCAGCCCCTCGCCCTCACCCGTGCCCAA
GAGCCCCTCTGTGGACAAGTACAACGTGAGCGGCACCAACGGGACCTGCCTGCTGGCCAGCATGGGGCTG
CAGCTGAACCTCACCTATGAGAGGAAGGACAACACGACGGTGACAAGGCTTCTCAACATCAACCCCAACA
AGACCTCGGCCAGCGGGAGCTGCGGCGCCCACCTGGTGACTCTGGAGCTGCACAGCGAGGGCACCACCGT
CCTGCTCTTCCAGTTCGGGATGAATGCAAGTTCTAGCCGGTTTTTCCTACAAGGAATCCAGTTGAATACA
ATTCTTCCTGACGCCAGAGACCCTGCCTTTAAAGCTGCCAACGGCTCCCTGCGAGCGCTGCAGGCCACAG
TCGGCAATTCCTACAAGTGCAACGCGGAGGAGCACGTCCGTGTCACGAAGGCGTTTTCAGTCAATATATT
CAAAGTGTGGGTCCAGGCTTTCAAGGTGGAAGGTGGCCAGTTTGGCTCTGTGGAGGAGTGTCTGCTGGAC
GAGAACAGCATGCTGATCCCCATCGCTGTGGGTGGTGCCCTGGCGGGGCTGGTCCTCATCGTCCTCATCG
CCTACCTCGTCGGCAGGAAGAGGAGTCACGCAGGCTACCAGACTATCTAGCCTGGTGCACGCAGGCACAG
CAGCTGCAGGGGCCTCTGTTCCTTTCTCTGGGCTTAGGGTCCTGTCGAAGGGGAGGCACACTTTCTGGCA
AACGTTTCTCAAATCTGCTTCATCCAATGTGAAGTTCATCTTGCAGCATTTACTATGCACAACAGAGTAA
CTATCGAAATGACGGTGTTAATTTTGCTAACTGGGTTAAATATTTTGCTAACTGGTTAAACATTAATATT
TACCAAAGTAGGATTTTGAGGGTGGGGGTGCTCTCTCTGAGGGGGTGGGGGTGCCGCTGTCTCTGAGGGG
TGGGGGTGCCGCTGTCTCTGAGGGGTGGGGGTGCCGCTCTCTCTGAGGGGGTGGGGGTGCCGCTTTCTCT
GAGGGGGTGGGGGTGCCGCTCTCTCTGAGGGGGTGGGGGTGCTGCTCTCTCCGAGGGGTGGAATGCCGCT
GTCTCTGAGGGGTGGGGGTGCCGCTCTAAATTGGCTCCATATCATTTGAGTTTAGGGTTCTGGTGTTTGG
TTTCTTCATTCTTTACTGCACTCAGATTTAAGCCTTACAAAGGGAAAGCCTCTGGCCGTCACACGTAGGA
CGCATGAAGGTCACTCGTGGTGAGGCTGACATGCTCACACATTACAACAGTAGAGAGGGAAAATCCTAAG
ACAGAGGAACTCCAGAGATGAGTGTCTGGAGCGCTTCAGTTCAGCTTTAAAGGCCAGGACGGGCCACACG
TGGCTGGCGGCCTCGTTCCAGTGGCGGCACGTCCTTGGGCGTCTCTAATGTCTGCAGCTCAAGGGCTGGC
ACTTTTTTAAATATAAAAATGGGTGTTATTTTTATTTTTTTTTGTAAAGTGATTTTTGGTCTTCTGTTGA
CATTCGGGGTGATCCTGTTCTGCGCTGTGTACAATGTGAGATCGGTGCGTTCTCCTGATGTTTTGCCGTG
GCTTGGGGATTGTACACGGGACCAGCTCACGTAATGCATTGCCTGTAACAATGTAATAAAAAGCCTCTTT
CTTTTAAAAAAAAAAAAAAAAAAAAAAAA

>PG355233.1 JP 2023526495-A/24: SARS-COV-2 VACCINES
GGCACCGATTCGGGGCCTGCCCGGACTTCGCCGCACGCTGCAGAACCTCGCCCAGCGCCCACCATGCCCC
GGCAGCTCAGCGCGGCGGCCGCGCTCTTCGCGTCCCTGGCCGTAATTTTGCACGATGGCAGTCAAATGAG
AGCAAAAGCATTTCCAGAAACCAGAGATTATTCTCAACCTACTGCAGCAGCAACAGTACAGGACATAAAA
AAACCTGTCCAGCAACCAGCTAAGCAAGCACCTCACCAAACTTTAGCAGCAAGATTCATGGATGGTCATA
TCACCTTTCAAACAGCGGCCACAGTAAAAATTCCAACAACTACCCCAGCAACTACAAAAAACACTGCAAC
CACCAGCCCAATTACCTACACCCTGGTCACAACCCAGGCCACACCCAACAACTCACACACAGCTCCTCCA
GTTACTGAAGTTACAGTCGGCCCTAGCTTAGCCCCTTATTCACTGCCACCCACCATCACCCCACCAGCTC
ATACAGCTGGAACCAGTTCATCAACCGTCAGCCACACAACTGGGAACACCACTCAACCCAGTAACCAGAC
CACCCTTCCAGCAACTTTATCGATAGCACTGCACAAAAGCACAACCGGTCAGAAGCCTGATCAACCCACC
CATGCCCCAGGAACAACGGCAGCTGCCCACAATACCACCCGCACAGCTGCACCTGCCTCCACGGTTCCTG
GGCCCACCCTTGCACCTCAGCCATCGTCAGTCAAGACTGGAATTTATCAGGTTCTAAACGGAAGCAGACT
CTGTATAAAAGCAGAGATGGGGATACAGCTGATTGTTCAAGACAAGGAGTCGGTTTTTTCACCTCGGAGA
TACTTCAACATCGACCCCAACGCAACGCAAGCCTCTGGGAACTGTGGCACCCGAAAATCCAACCTTCTGT
TGAATTTTCAGGGCGGATTTGTGAATCTCACATTTACCAAGGATGAAGAATCATATTATATCAGTGAAGT
GGGAGCCTATTTGACCGTCTCAGATCCAGAGACAGTTTACCAAGGAATCAAACATGCGGTGGTGATGTTC
CAGACAGCAGTCGGGCATTCCTTCAAGTGCGTGAGTGAACAGAGCCTCCAGTTGTCAGCCCACCTGCAGG
TGAAAACAACCGATGTCCAACTTCAAGCCTTTGATTTTGAAGATGACCACTTTGGAAATGTGGATGAGTG
CTCGTCTGACTACACAATTGTGCTTCCTGTGATTGGGGCCATCGTGGTTGGTCTCTGCCTTATGGGTATG
GGTGTCTATAAAATCCGCCTAAGGTGTCAATCATCTGGATACCAGAGAATCTAATTGTTGCCCGGGGGGA
ATGAAAATAATGGAATTTAGAGAACTCTTTCATCCCTTCCAGGATGGATGTTGGGAAATTCCCTCAGAGT
GTGGGTCCTTCAAACAATGTAAACCACCATCTTCTATTCAAATGAAGTGAGTCATGTGTGATTTAAGTTC
AGGCAGCACATCAATTTCTAAATACTTTTTGTTTATTTTATGAAAGATATAGTGAGCTGTTTATTTTCTA
GTTTCCTTTAGAATATTTTAGCCACTCAAAGTCAACATTTGAGATATGTTGAATTAACATAATATATGTA
AAGTAGAATAAGCCTTCAAATTATAAACCAAGGGTCAATTGTAACTAATACTACTGTGTGTGCATTGAAG
ATTTTATTTTACCCTTGATCTTAACAAAGCCTTTGCTTTGTTATCAAATGGACTTTCAGTGCTTTTACTA
TCTGTGTTTTATGGTTTCATGTAACATACATATTCCTGGTGTAGCACTTAACTCCTTTTCCACTTTAAAT
TTGTTTTTGTTTTTTGAGACGGAGTTTCACTCTTGTCACCCAGGCTGGAGTACAGTGGCACGATCTCGGC
TTATGGCAACCTCCGCCTCCCGGGTTCAAGTGATTCTCCTGCTTCAGCTTCCCGAGTAGCTGGGATTACA
GGCACACACTACCACGCCTGGCTAATTTTTGTATTTTTATTATAGACGGGTTTCACCATGTTGGCCAGAC
TGGTCTTGAACTCTTGACCTCAGGTGATCCACCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATG
AGCCATTGCGCCCGGCCTTAAATGTTTTTTTTAATCATCAAAAAGAACAACATATCTCAGGTTGTCTAAG
TGTTTTTATGTAAAACCAACAAAAAGAACAAATCAGCTTATATTTTTTATCTTGATGACTCCTGCTCCAG
AATTGCTAGACTAAGAATTAGGTGGCTACAGATGGTAGAACTAAACAATAAGCAAGAGACAATAATAATG
GCCCTTAATTATTAACAAAGTGCCAGAGTCTAGGCTAAGCACTTTATCTATATCTCATTTCATTCTCACA
ACTTATAAGTGAATGAGTAAACTGAGACTTAAGGGAACTGAATCACTTAAATGTCACCTGGCTAACTGAT
GGCAGAGCCAGAGCTTGAATTCATGTTGGTCTGACATCAAGGTCTTTGGTCTTCTCCCTACACCAAGTTA
CCTACAAGAACAATGACACCACACTCTGCCTGAAGGCTCACACCTCATACCAGCATACGCTCACCTTACA
GGGAAATGGGTTTATCCAGGATCATGAGACATTAGGGTAGATGAAAGGAGAGCTTTGCAGATAACAAAAT
AGCCTATCCTTAATAAATCCTCCACTCTCTGGAAGGAGACTGAGGGGCTTTGTAAAACATTAGTCAGTTG
CTCATTTTTATGGGATTGCTTAGCTGGGCTGTAAAGATGAAGGCATCAAATAAACTCAAAGTATTTTTAA
ATTTTTTTGATAATAGAGAAACTTCGCTAACCAACTGTTCTTTCTTGAGTGTATAGCCCCATCTTGTGGT
AACTTGCTGCTTCTGCACTTCATATCCATATTTCCTATTGTTCACTTTATTCTGTAGAGCAGCCTGCCAA
GAATTTTATTTCTGCTGTTTTTTTTGCTGCTAAAGAAAGGAACTAAGTCAGGATGTTAACAGAAAAGTCC
ACATAACCCTAGAATTCTTAGTCAAGGAATAATTCAAGTCAGCCTAGAGACCATGTTGACTTTCCTCATG
TGTTTCCTTATGACTCAGTAAGTTGGCAAGGTCCTGACTTTAGTCTTAATAAAACATTGAATTGTAGTAA
AGGTTTTTGCAATAAAAACTTACTTTGG

